MedTrace Logo

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

NCT01573351 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 398

Last updated 2015-10-09

No results posted yet for this study

Summary

The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) \< Limit of quantitation (LOQ) at post-treatment Week 12.

Conditions

  • Hepatitis C Virus

Interventions

DRUG

Asunaprevir

DRUG

Daclatasvir

DRUG

Peg-interferon Alfa-2a

DRUG

Ribavirin

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-09-30
Completion
2013-12-31

Countries

  • United States
  • Argentina
  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Mexico
  • Netherlands
  • Russia
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01573351 on ClinicalTrials.gov